top of page
Previous postdocs and students from the Arginine Methylation Laboratory
Moving on to new pastures, but still very much missed
Dr Agnieszka Zielinska
After completing her post-doc in the Davies Lab working on the identification of novel PRMT1 substrates in breast cancer and developing state-of-the-art in vivo mouse techniques, Agnieszka is now working as a technical manager at the University of Birmingham.
Dr Pilar Sanchez-Bailon
Pilar identified the deubiquitylating enzyme, USP11, as a new PRMT1 substrate and has characterised a role for methyl-USP11 in the repair of double strand breaks by homologous recombination. She is now completing a second post-doc in the Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.
Dr Debashish Sahay
Debashish worked on drug treating breast cancer xenograft models with pre-clinical PRMT5 inhibitors to understand breast cancer stem cell function. He has now moved to the USA to work with Johnson and Johnson Pharmaceuticals.
Dr Thomas Clarke
After completing his PhD in the Davies Lab understanding how PRMT5 regulates homologous-recombination-mediated DSB repair, Tom was awarded an EMBO Long-Term Fellowship to join the lab of Dr Johnathan Whetstine (MGH, Harvard) to work on lysine demethylases and aberrant copy number gains in cancer. He is now working in the lab of Dr Raul Mostoslavsky, (MGH, Harvard) investigating acetylation and the DNA damage response.
Dr James Jarrold
After completing a PhD using quantitative proteomics to understand how PRMT1 functions in breast cancer, James is now working as a post-doc at Warwick University.
Dr Krystian Ubych
School of Chemisty, with Dr. Rob Neely
Krystian completed his PhD in the lab of Dr. Robert Neely and Dr. Francisco Fernandez-Trillo (University of Birmingham) and was involved in studies of DNA methylation using a combination of organic chemistry, enzyme-based methods and fluorescence imaging. During this time, I got an opportunity to explore the epigenetics of cancer thanks to collaboration with Dr. Clare Davies’ group. After a short postdoc in the Neely lab, Krystian is now a Senior Scientist at Tagomics Ltd, Birmingham.
Dr Matthew Gillespie
Matthew's PhD studies involved understanding the role of PRMT5 in promoting chemoresistance of breast cancer stem cells. He is now working as a post-doc at Southampton University.
Since investigating RUVBL1 methylation in breast cancer, Lauren has moved to Germany and is starting a PhD studentship soon.
Sophie was developing new approaches to trace BCSC.
Undergraduate professional training year (Cardiff University)
After studying the role of FXR1 during DNA repair, Fiona is now completing a CRUK funded PhD at the UCL Cancer Institute, London, investigating PTEN in cancer under the supervision of Prof. Bart Vanhaesebroeck.
Since analysing our PRMT1 mass spectrometry data set, and further investigating FXR1 in DNA repair, Hannah is now an iCASE PhD student at the Barts Cancer Institute, London.
Kerianne, having completed her MRes on bio-orthogonal profiling for PRMTs, is now working as a marketing analyst at Calibre Scientific Inc.
Since his delve into PADI enzymes and citrullination, Zac is at the lab of Dr. Cristine Schmidt, University of Manchester completing a PhD studying ubquitin-like modifiers in the DNA damage response.
Lisa developed a new way in which to capture methylated proteins for mass spectrometry analysis, and is now completing a PhD in Munich, Germany.
James Van Hear
Jimmy worked on methyl-RUVBL1 and c-Myc-mediated gene expression. He is conducting a PhD at UCL, London, working on wound healing in cancer organoids.
Sophie also worked on methyl-RUVBL1 and c-Myc-mediated gene expression, and is now at the University of Birmingham clinical trials department.
Wendy investigated phosphorylation-dependent regulation of PRMT1 activity, and is a PhD student at the University of Birmingham on the BBSRC MIBTP doctoral training programme.
Summik studied RACO-1 in breast cancer, and is now a PhD student at Imperial College, London.
bottom of page